°£¾Ï °ËÁø ±Ç°í¾È
The Korean guideline for hepatocellular carcinoma surveillance
´ëÇÑÀÇ»çÇùȸÁö 2015³â 58±Ç 5È£ p.385 ~ p.397
±èµµ¿µ(Kim Do-Young) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±èÇöÁ¤(Kim Hyun-Jung) - °í·Á´ëÇб³ ÀÇ°ú´ëÇÐ ¿¹¹æÀÇÇб³½Ç
Á¤½ÂÀº(Jung Seung-Eun) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ¹æ»ç¼±°úÇб³½Ç ¿µ»óÀÇÇаú
±è»ó±Õ(Kim Sang-Gyune) - ¼øõÇâ´ëÇб³ ÀÇ°ú´ëÇÐ ¼Òȱ⳻°ú
±èÇüÁØ(Kim Hyung-Joon) - Áß¾Ó´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
½Åµ¿Çö(Sinn Dong-Hyun) - ¼º±Õ°ü´ëÇб³ »ï¼º¼¿ïº´¿ø ¼Òȱ⳻°ú
ÀÌ¿ëÁÖ(Lee Yong-Joo) - °¡Å縯´ëÇб³ ¼¿ï¼º¸ðº´¿ø °¡Á¤ÀÇÇаú
Á¤¿ì°æ(Jeong Woo-Kyoung) - »ï¼º¼¿ïº´¿ø ¿µ»óÀÇÇаú
Ãֱͼ±(Choi Kui-Son) - ±¹¸³¾Ï¼¾ÅÍ ±¹Á¦¾Ï´ëÇпø´ëÇб³
Çã³»À±(Heo Nae-Yun) - ÀÎÁ¦´ëÇб³ ÀÇ°ú´ëÇÐ ÇØ¿î´ë¹éº´¿ø ³»°úÇб³½Ç
±èµ¿ÁØ(Kim Dong-Joon) - ÇѸ²´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±è¿µ¼®(Kim Young-Seok) - ¼øõÇâ´ëÇб³ ÀÇ°ú´ëÇÐ ¼Òȱ⳻°ú
±è¿ë¹ü(Kim Yong-Bum) - À§¾ØÀåÂü»ç¶û³»°úÀÇ¿ø
±èÀ±ÁØ(Kim Yoon-Jun) - ¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±èÇü·Ä(Kim Hyoung-Ryoul) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ¿¹¹æÀÇÇб³½Ç ¹× Á÷¾÷ȯ°æÀÇÇм¾ÅÍ
¹Ú¹Î¼±(Park Min-Seon) - ¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ °¡Á¤ÀÇÇб³½Ç
ÀÌÂùÈ(Lee Chan-Wha) - ±¹¸³¾Ï¼¾ÅÍ ¿µ»óÀÇÇаú
Ź¿ø¿µ(Tak Won-Young) - °æºÏ´ëÇб³º´¿ø ¼Òȱ⳻°ú
Á¤ÁöÇý(Chung Ji-Hye) - ±¹¸³¾Ï¼¾ÅÍ ±¹°¡¾Ï°ü¸®»ç¾÷´Ü
±è¼ö¿µ(Kim Soo-Young) - ÇѸ²´ëÇб³ ÀÇ°ú´ëÇÐ °µ¿¼º½Éº´¿ø °¡Á¤ÀÇÇаú
±è¿(Kim Yeol) - ±¹¸³¾Ï¼¾ÅÍ ±¹°¡¾Ï°ü¸®»ç¾÷º»ºÎ
ÀÌ¿øö(Lee Won-Chul) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ¿¹¹æÀÇÇб³½Ç
±èÈ«¼ö(Kim Hong-Soo) - ¼øõÇâ´ëÇб³ ÀÇ°ú´ëÇÐ ¼Òȱ⳻°ú
Abstract
Hepatocellular carcinoma (HCC) is one of the major cancers with a high incidence and mortality in Korea. A Korean
multidisciplinary collaborative committee consisting of hepatologists, radiologists, epidemiologists and family medicine
doctors systematically reviewed clinical practice guidelines in the world and literatures. The level of evidence for each
recommendation was assessed and discussed to reach a consensus. Meta-analysis was also conducted to evaluate
the grade of recommendation for the five key questions. Several randomized controlled studies and cohort studies
showed a survival gain associated with surveillance for those at risk of developing HCC. The target populations for HCC
surveillance were identified as hepatitis B virus or hepatitis C virus carriers and cirrhotic patients, since numerous studies
revealed that these patients have significantly higher risk of HCC compared with non-infected or non-cirrhotic controls.
Individual surveillance strategy according to treatment history or degree of fibrosis in patients with viral hepatitis remains
to be settled. Based on several cohort and randomized studies, a surveillance interval of six months was recommend.
The starting age of surveillance was determined as 40 years from the epidemiologic data. Although ultrasonography
(US) is the mainstay for detection of HCC, its sensitivity is not fully accepted. Measurement of serum alpha-fetoprotein
can complement US examination, increasing the sensitivity of HCC detection. The recommendation for HCC surveillance
is that those with hepatitis B virus (or hepatitis C virus) infection or cirrhosis should have liver US and serum alphafetoprotein
measurement every six months from 40 years of age or at the time of diagnosis of cirrhosis.
Å°¿öµå
Hepatocellular carcinoma, Surveillance, Ultrasonography, Alpha-fetoprotein
KMID :
0614720150580050385
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
The recommendation for HCC surveillance is that those with hepatitis B virus (or hepatitis C virus) infection or cirrhosis should have liver US and serum alphafetoprotein measurement every six months from 40 years of age or at the time of diagnosis of cirrhosis.